Targets for Cancer IO: A Deep Dive Webinar Series - Enduring Materials

Targets for Cancer Immunotherapy: A Deep Dive

The Society for Immunotherapy of Cancer (SITC) is pleased to offer a second series of nine, online seminars to address key questions in the field of cancer immunotherapy, both in-depth and in an easily accessible format.

Each of the nine seminars will feature leaders in the immuno-oncology field who are experts in a given subject area to provide an overview of the current scientific knowledge about a therapy. An interactive Q&A session will follow the topic overview, providing participants with the opportunity to ask in-depth questions of the faculty as well as offering a forum for networking and initiation of collaborations with others working in a similar field.

NOTE: You must be logged into your SITC CONNECT account to view on-demand content.

Series 2 Enduring Materials 

Seminar 1 – LAG-3 BIOLOGY AND CURRENT CLINICAL RESULTS

• Date of Live Event: Monday, June 13, 2022 – 12 p.m.–2 p.m. CDT
• Moderators:
  • Drew M. Pardoll, MD, PhD – Johns Hopkins University
  • Dario A.A. Vignali, PhD – University of Pittsburgh
• Faculty:
  • Tullia C. Bruno, PhD – University of Pittsburgh
  • Evan J. Lipson, MD – Johns Hopkins University
  • Dario A.A. Vignali, PhD – University of Pittsburgh

Seminar 2 – RECOMBINANT INTERLEUKIN-18 IMMUNOTHERAPY

• Date of Live Event: Monday, July 18, 2022
  
• Moderators:
• Michael T. Lotze, MD, FACS – Nurix Therapeutics
• Aaron M. Ring, MD, PhD – Yale University School of Medicine
• Faculty:
  • Scott W. Canna, MD - University of Pennsylvania, The Children's Hospital of Philadelphia
    
  • Simone A. Minnie, PhD - Fred Hutchinson Cancer Research Center

Seminar 3 – TIL Therapies

• Date of Live Event: Monday, July 28, 2022
  
• Moderators:
• Brian R. Gastman, MD – Cleveland Clinic Cancer Center
  
• Stephanie L. Goff, MD, FACS – National Cancer Institute Surgery Branch
  
• Faculty:
  • Giacomo Oliveira, PhD - Dana Farber Cancer Institute
    
  • Amod Sarnaik, MD - H. Lee Moffit Cancer Center and Research Institute
    

Seminar 4 – Targeted systemic delivery of innate immune activators

• Date of Live Event: Friday, August 26, 2022
  
• Moderators:
  • Timothy Lowinger, PhD – Mersana Therapeutics
  • Valerie Odegard, PhD - Silverback Therapeutics
• Faculty:
  • Timothy Lowinger, PhD – Mersana Therapeutics
  • Valerie Odegard, PhD - Silverback Therapeutics
  • Trevor Hallam, PhD - Sutro Biopharma

Seminar 5 – Scientific basis of b-cell modulation for anti-tumor immunity

• Date of Live Event: Thursday, September 15, 2022
  
• Moderators:
  • Tullia Bruno, PhD - Univeristy of Pittsburgh
    
  • Daniel Hollern, PhD - The Salk Institute of Biological Studies
    
• Faculty:
  • Brad Nelson, PhD – BC Cancer-Deeley Research Center
    
  • Yuliya Pylayeva-Gupta, PhD - UNC at Chapel Hill
    
  • Karen Willard-Gallo, PhD - Institut Jules Bordet
    

Seminar 6 – IPSC CELL DERIVED THERAPIES

• Date of Live Event: Monday, September 26, 2022
  
• Moderators:
  • Kalle Malmberg, MD, PhD – Oslo University Hospital
  • Jeffrey S. Miller, MD – University of Minnesota
• Faculty:
  • Ran Jing, PhD – Boston Children’s Hospital
  • Sjouke van der Stegen, PhD – Memorial Sloan Kettering

Seminar 7 – Enhanced CTLA-4 Blockade

• Date of Live Event: Wednesday, October 5, 2022
  
• Moderators:
  • James P. Allison, PhD, FAIO – The University of Texas MD Anderson Cancer Center
  • Alan J. Korman, PhD, FAIO – Vir Biotechnology
    
• Faculty:
  • Aurelien Marabelle, MD, PhD – Gustave Roussy
  • Simon J. Dovedi, PhD – AstraZeneca
  • Nick Wilson, PhD – Bristol Myers Squibb
  • Dhan Chand, PhD – Agenus

Webinar 8 – TCR Based Therapeutics

• Date of Live Event: Wednesday, Dec. 7, 2022 – 2 p.m.–4 p.m. CST
• Moderators:
  
  • Harlan Robins, PhD – Adaptive Biotechnologies Corporation
• Faculty:
  • David Berman, MD, PhD - Immunocore
  • Aude Chapuis, MD - Fred Hutchinson Cancer Center
  • Ira Mellman, PhD - Genentech

Live Webinar 9 – NK cell engagers  

• Date of Live Event: Wednesday, Jan. 11, 2023 – 10 a.m.–12 p.m. CST
• Moderators:
  
  • Adelheid Cerwenka, PhD – Heidelberg University
  • Lewis L. Lanier, PhD – University of California, San Francisco
• Faculty:
  • Sarah Cooley, MD - Fate Therapeutics
  • Martin Felices, PhD - University of Minnesota
  • Eric Vivier, DVM, PhD - Innate Pharma

Targets for Cancer IO: A Deep Dive Series 2 is supported, in part, by educational grants from Genmab, US, Inc. Iovance Biotherapeutics, and Merck & Co., Inc.


Interested in supporting this program? The SITC Development team would love to work with you. Contact Development@sitcancer.org for more information on how your organization's support can help advance cancer immunotherapy and make "cure" a reality.

Purchase Prices

Purchase Form

If you have questions about this seminar series, please contact the SITC Education team.